BioCryst Announces Initiation of the Phase 3 APeX-2 Trial of BCX7353 in Patients with Hereditary Angioedema

BioCryst Pharmaceuticals (NASDAQ:BCRX) announced today the dosing of the first patient into APeX-2, a Phase 3 clinical trial evaluating two dosage strengths of BCX7353 administered orally once-daily (QD)  as a preventive treatment to reduce the frequency of attacks in patients with hereditary angioedema (HAE).

As quoted in the press release:

“The ability to safely prevent attacks of angioedema with an oral medicine has been a dream for many HAE patients.  Today marks a significant milestone toward the realization of that dream,” said Bruce Zuraw, MD and Principal Investigator of the APeX-2 trial. “I am excited to be able to participate in this important trial, which we believe will lead to an effective oral prophylactic treatment offering HAE patients the opportunity to lead a normal life.”

Click here to read the full press release.